Delivery Order SPE2DB22D2005-SPE2DB24FJQA4

Award Date 7/15/24
Potential Completion Date 8/5/24
Potential Value $2.8K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, for the supply of 1,500 units of HYPERRHO S-D syringes. The contract has a ceiling value of $4,629.80 and is a firm fixed price delivery order, with a completion date of May 20, 2024. The contract was awarded on April 29, 2024 and does not have a set-aside designation. Amerisourcebergen Drug Corp's Corporate Office Division is the prime...
This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, was issued by the Defense Logistics Agency (DLA) Troop Support Medical. The contract, valued at $1,467.60, is a delivery order for the supply of 4557786416 HYPERRHO S-D 250 UNIT SYRINGES. The contract has a firm fixed price pricing type and an ultimate completion date of August 3, 2022. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
This federal contract award to Amerisourcebergen Drug Corp's Corporate Office Division is for the delivery of 1,500 unit syringes under the product name "HYPERRHO S-D" with a ceiling value of $1,388.94. The contract is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA), a defense agency, on June 20, 2024, with a completion date of July 12, 2024. This award is not designated as a set-aside contract. Amerisourcebergen Drug Corp is a major supplier of...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $2,205.58, is for the delivery of HYPERRAB 300 UNIT/ML VIAL 3ML medical products. It is a firm fixed price contract with a completion date of July 15, 2025. The contract is not set aside for any specific business type. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $10,744.80, is for the delivery of HYPERRAB 300 UNIT/ML VIAL 5ML medical supplies. The contract is not set-aside and has an ultimate completion date of June 25, 2025. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $18,783.50 firm fixed-price contract is for the supply of HYPERRAB 300 UNIT/ML VIAL 5ML, a medical product used for infectious disease prevention and treatment. The contract has an ultimate completion date of December 5, 2024. Amerisourcebergen holds a larger $999,999,999 Indefinite Delivery Contract (IDC) with...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of HYPERRAB 300 UNIT/ML VIAL 5ML, a pharmaceutical product. The contract is a firm fixed price delivery order with a ceiling value of $7,163.24 and a period of performance through June 13, 2025. The contract is not set aside for any special program. Amerisourcebergen Drug Corp holds a...
This is a federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, by the Defense Logistics Agency (DLA) Troop Support Medical. The $11,628.54 delivery order contract is for the provision of HYPERTET 250 UNIT/ML SYRINGEML medical supplies, with a completion date of July 10, 2025. The contract is a firm fixed-price delivery order and is not set aside. Amerisourcebergen Drug Corp holds a significant $999,999,999.00 Indefinite...
This is a federal contract award from the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order with a firm fixed price of $14,326.40 and a completion date of May 8, 2025. The contract is not set aside and involves the procurement of HYPERRAB 300 UNIT/ML VIAL 5ML, a medical product. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with DLA Troop...
This is a delivery order awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of HYPERRAB 300 UNIT/ML VIAL 5ML. The delivery order is valued at $3,756.72 and has a firm fixed-price pricing structure. The ultimate completion date for this contract is August 27, 2024. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to...
  • SPE2DB22D2005
    Indefinite Delivery Contract
  • SPE2DB22D2005-SPE2DB24FJQA4
    Delivery Order

This firm fixed-price delivery order contract was awarded to Amerisourcebergen Drug Corp's Corporate Office Division by the Defense Logistics Agency (DLA) on July 15, 2024. The contract, worth $2,777.88, is for the delivery of 1,500 unit syringes of HYPERRHO S-D, a pharmaceutical product, with a completion date of August 5, 2024. This order is placed under Amerisourcebergen's Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at up to $999,999,999.00 through December 31, 2025, which serves as the primary vehicle for the company to deliver a comprehensive range of pharmaceutical products and medical supplies to DLA facilities supporting the Department of Defense worldwide. The contract does not have a set-aside designation.

Generated 10/14/24, 10:02 AM